Enacts new GS 58-51-59.1 requiring every policy or contract of accident or health insurance and every preferred provider benefit plan that provides coverage for cancer treatment to provide coverage for prescribed, oral anticancer drugs that kill or slow the growth of cancer cells on a basis no less favorable than provided for intravenously administered or injected cancer drugs. Prohibits coverage for orally administered anticancer drugs from being subject to prior authorization, dollar limit, co-payment, coinsurance, deductible provision, or any other out of pocket expense that dose not apply to intravenously administered or injected anticancer drugs. Prohibits achieving compliance by reclassifying drugs or increasing expenses imposed on anticancer drugs.

Applies to insurance contracts issued, renewed, or amended on or after January 1, 2014.